Robitussin Drowsiness False Ad Settlement: $4.5M

• Consumers who purchased certain Robitussin products containing dextromethorphan that were marketed as “non-drowsy” during the eligibility period.
  
  
• Covered products include various Robitussin syrups, capsules, and gels, including Robitussin 12-Hour Cough Relief, Robitussin Cough + Chest Congestion DM, and Children’s Robitussin products.
  
  
• A full list of eligible products is available on the settlement website.

To claim higher reimbursement amounts, class members must provide proof of purchase, such as:

• Receipts
• Invoices
• Bank or credit card statements
• Retailer order confirmations

Haleon, the maker of Robitussin cough and cold products, has agreed to pay $4.5 million to settle a class action lawsuit that claims it falsely advertised certain Robitussin products as "non-drowsy" despite containing dextromethorphan, an ingredient that can cause drowsiness.

The lawsuit alleges that Haleon misled consumers by labeling its products as “non-drowsy” while scientific research and FDA warnings have noted that dextromethorphan can cause drowsiness in some individuals. Plaintiffs argue they would not have purchased these products—or would have paid less—had they known the truth about the effects of the medication.

Robitussin is a popular cough and cold medicine brand offering products for both adults and children.

While denying any wrongdoing, Haleon has agreed to settle the case to resolve the claims and provide compensation to affected consumers.

Settlement Benefits

• Cash Payment Per Claim:
  • With proof of purchase – up to three claims per person
  • Without proof of purchase – limited to one claim per person
  • Estimated payout per claim: $1.50 to $4.75, depending on the number of claims filed

If you purchased a Robitussin product labeled "non-drowsy" and believe you were misled, check your eligibility and submit your claim before the deadline to receive a cash payment.